Abstract:The current review described a 55-year woman using 28 months to finish her surgery-based radiation-free multimodality treatment journey to fight International Federation of Gynaecology & Obstetrics (FIGO) 2018 clinical stage IIA2 (cT2aN0M0) squamous cell carcinoma (SCC) of the cervix. She received six cycles of perioperative adjuvant therapy, including three cycles of neoadjuvant therapy (NAT) and three cycles of postoperative adjuvant therapy by using combination of dose-dense chemotherapy (CT, weekly paclitaxel 80 mg/m2+triweekly cisplatin 40 mg/m2), immunotherapy (IO, triweekly pembrolizumab 200 mg) and half-dose anti-angiogenic agent (triweekly bevacizumab 7.5 mg/kg) plus interval radical surgery (radical hysterectomy + bilateral salpingo-oophorectomy + bilateral pelvic lymph node dissection + para-aortic lymph node sampling) and following maintenance therapy with monthly 22 cycles of half-dose of IO (pembrolizumab 100 mg) and concomitant 4 cycles of single-agent CT (paclitaxel 175 mg/m2) and 18 cycles of half-dose anti-angiogenic agent (bevacizumab 7.5 mg/kg). During the cervical SCC fighting journey, two unwanted adverse events (AEs) occurred. One was pseudo-progressive disease during the NAT treatment and pathology-confirmed upgrading FIGO stage IIIC1p (ypT2a1N1M0) after radical surgery and the other was the occurrence of hypothyroidism during the post operative adjuvant therapy. Based on this case we presented, we review the recent trend in the management of women with locally advanced cervical cancer (LACC) using the radiation-free but surgery-based multimodality strategy and highlight the strengths and limitations about perioperative adjuvant therapy with dose-dense CT + IO + half-dose anti-angiogenic agent and maintenance treatment of half-dose IO combining with short-term single agent CT and following long-term half-dose anti-angiogenic agent. All underscore the possibility that women with LACC have an opportunity to receive surgery-based RT-free multi-modality strategy to manage their diseases with satisfactory results. Additionally, the evolving role of IO plus CT with/without anti-angiogenic agent functioning as either primary treatment or adjuvant therapy for the treatment of advanced CC has been in process continuously. Moreover, the patient's positive response to IO, pembrolizumab as an example, both during the primary and maintenance therapy, highlights the importance of integrating IO into CT regimens for CC, especially in cases where conventional therapies, RT as an example, are insufficient or who do not want to receive RT-based treatment. The sustained disease-free status of the patient over several years reinforces the potential of IO to significantly increase long-term survival outcomes in CC patients, particularly for those with LACC.

Combined modality management of advanced cervical cancer including novel sensitizers

Advances in Nonsurgical Treatment of Head and Neck Squamous Cell Carcinoma

Combined modality including novel sensitizers in gynecological cancers

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Surgery-based radiation-free multimodality treatment for locally advanced cervical cancer

Management for locally advanced cervical cancer: new trends and controversial issues

Advances in Radiation Oncology for the Treatment of Cervical Cancer

Evolving standards and future directions for systemic therapies in cervical cancer

Pharmacodynamics of current and emerging treatments for cervical cancer

Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer

Multimodality management of locally advanced gastric cancer-the timing and extent of surgery

Management of Early-Stage Cervical Cancer: A Literature Review

Global challenges of radiotherapy for the treatment of locally advanced cervical cancer

Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I)

Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin

Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy

New Frontiers in Locally Advanced Cervical Cancer Treatment

Treatment strategies in cervical cancer: treatment of advanced disease

Cervical cancer: a new era

Surgical Treatment Combined with Postoperative Adjuvant Chemotherapy Offer a Viable Option to the Cervical Cancer in Stage ⅠB～ⅡA with Moderate and High-risk Factor for Recurrence

Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists